LGND LIGAND PHARMACEUTICALS INC

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: biopharmaceutical royalty company focused on capital deployment and licensing for diversified royalty streams from mid- to late-stage products
• • New emphasis on NITRICIL platform acquired via Novan in 2023, supporting multiple royalty-bearing products including FDA-approved Zelsuvmi
• • Strategic refinement since 2022 to a high-margin, low-infrastructure model after spinoffs of OmniAb, Pelican Expression, and Pelthos Therapeutics
• • Invested $50 million in Castle Creek's D-Fi Phase 3 gene therapy and $25 million in Orchestra BioMed late-stage cardiology programs in 2025
• • Expanded royalty portfolio to 12 major commercial royalties and over 90 additional programs, showing growing diversity and disciplined capital allocation

Risk Factors

• • Regulatory risk: Section 162(m) limitation increased tax expense by $3.9 million (156%) in 2024 affecting effective tax rate
• • Macroeconomic threat: $460 million 2030 Notes issued in August 2025 increases interest expense by $1.7 million (55%) vs prior year
• • Operational risk: Deconsolidation of Novan acquisition payments from July 1, 2025 impacts interest accrued and financial reporting
• • Market disruption risk: Unrealized fair value loss $5.1 million on Viking common stock in 2025 vs $9.0 million gain in 2024
• • Financial risk: Concentration in equity method investments, e.g., $90.7 million gain from Pelthos stock fair value changes in 2025

Management Discussion & Analysis

• • Revenue and profit details not provided in the excerpt
• • No segment performance data disclosed in the excerpt
• • No cash flow, buybacks, dividends, or capex information included
• • No forward-looking statements or guidance mentioned

What are the latest LGND SEC filings in 2026?

LIGAND PHARMACEUTICALS INC (LGND) has filed a 10-K annual report on February 27, 2026, a 10-Q quarterly report on May 8, 2026, an 8-K current report on August 6, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did LGND file its most recent 10-K annual report?

LIGAND PHARMACEUTICALS INC (LGND) filed its most recent 10-K annual report on February 27, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view LGND 10-Q quarterly reports?

LIGAND PHARMACEUTICALS INC (LGND)'s most recent 10-Q quarterly report was filed on May 8, 2026. SignalX displays every LGND 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has LGND filed recently?

LIGAND PHARMACEUTICALS INC (LGND)'s most recent 8-K was filed on August 6, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find LGND insider trading activity (Form 4)?

SignalX aggregates every LGND Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does LGND file with the SEC?

LIGAND PHARMACEUTICALS INC (LGND) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new LGND filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for LIGAND PHARMACEUTICALS INC (LGND).

What is LGND's SEC CIK number?

LIGAND PHARMACEUTICALS INC (LGND)'s SEC CIK (Central Index Key) number is 886163. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 886163 to look up all LGND filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find LGND return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from LIGAND PHARMACEUTICALS INC (LGND) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.